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Introduction
Failure of effective tumour antigen presentation is thought to be one mechanism by which tumours evade immune destruction. 1 
Presentation of endogenous tumour antigen to CD8
+ T-lymphocytes via the MHC class-I pathway is a critical component in the induction of cell-mediated antitumour immunity. While many tumours are capable of displaying tumour antigens in the context of MHC class-I molecules, they lack the costimulatory signals necessary for successful T-lymphocyte activation. Conversely, professional antigen presenting cells (APC) possess the requisite costimulatory signals, but process and present captured tumour antigen predominantly via the MHC class-II pathway leading to the activation of CD4
+ rather than CD8 + T-lymphocytes. 2, 3 Although cross-priming of the MHC class-I pathway with captured antigen has been reported in a subset of APCs under defined conditions, the biological significance of this phenomenon in the context of tumour immunology remains to be defined. 4, 5 Intensive research efforts are currently being directed at defining therapeutic strategies that bypass these inherent limitations in the induction of antitumour immunity. These strategies include the expression of costimulatory molecules on tumour cells 6 and ex vivo manipulation of APC such that tumour antigens are presented by MHC class-I molecules. Among professional APC, which include macrophages, B-lymphocytes and dendritic cells (DC), DC are the most potent stimulators of antigen-specific T-lymphocyte responses. 7, 8 This potency, combined with the recent development of in vitro methods for the derivation of large numbers of DC from CD34
+ haematopoietic progenitor cells [9] [10] [11] or peripheral blood mononuclear cells (PBMC) 12, 13 make DC a prime target for therapeutic manipulation. As a consequence, induction of antitumour immune responses by DC after ex vivo antigen loading is currently subject to vigorous investigation. 8, 14, 15 Antigen-loaded murine DC have been shown to induce antigen-specific cytotoxic T-lymphocytes (CTL) and concomitant therapeutic antitumour immunity in murine models. [16] [17] [18] [19] [20] [21] [22] [23] [24] Results from limited human clinical experimentation, are also encouraging. 25, 26 Antigen loading has been achieved using a variety of strategies including direct delivery of exogenous peptide fragments or tumour extracts, [16] [17] [18] 21 or by endogenous antigen expression and processing within DC after delivery of antigen-encoding RNA or DNA molecules. [19] [20] [21] [22] [23] [24] 27 The extent to which these different approaches influence the efficiency of antigen-specific T-lymphocyte activation remains to be defined, although the advantages of expressing antigen-encoding genes in DC are compelling. Endogenous antigen expression and processing circumvents the MHC restriction imposed by the use of pep-tides, allows multiple undefined epitopes to be selected and presented to the immune system and should facilitate more efficient class-I loading and more persistent MHC-peptide complex presentation. In addition to genes encoding tumour antigens, DC might also be modified with cytokine genes to bias immune responses or with genes from human pathogens as a form of vaccination. Independent of these exciting therapeutic possibilities, genetic modification of DC should also be a powerful tool for the further analysis of DC function.
Mature DC are relatively refractory to standard physico-chemical gene transfer methods. 28 In contrast, recombinant adenovirus vectors have been used to achieve efficient gene transfer and expression (transduction) in both murine and human DC. 19, [22] [23] [24] [28] [29] [30] Moreover, murine DC genetically modified by adenovirus transduction have been shown to induce antigen-specific therapeutic antitumour immunity. 19, 22, 24 While murine studies using human-tropic adenovirus vectors are promising, these findings are not necessarily predictive of the outcome of experiments using human DC, because the adenovirus vectors used retained the capacity for viral gene expression [31] [32] [33] [34] and the potential to have different effects on function in mouse and human cells. 35 Human DC have been successfully transduced using adenovirus vectors with efficiencies exceeding 90% at high MOI. 28, 30 In one of these studies the immunophenotype of target DC was shown to be preserved despite adenovirus transduction, 28 but to date there are no published data addressing the critically important issue of whether adenovirus-transduced human DC remain capable of inducing antigen-specific CTL responses against a vector-encoded antigen. In the current study we set out to examine in vitro the utility of adenovirus vectors in the transduction of human PBMC-derived DC and to demonstrate whether transduced DC retain the capacity to induce antigen-specific CTL responses against a vectorencoded antigen. For transduction we employed an E1/E3-deleted adenovirus type 5 vector encoding ␤-gal under the transcriptional control of a CMV promoter. In addition to confirming efficient adenovirus transduction of DC and retention of key cell surface molecules involved in T-lymphocyte activation, we demonstrate retention of potency in allogeneic lymphocyte proliferation assays and most significantly induction of CTL reactive against the vector-encoded antigen, ␤-gal. These data have important implications for immunotherapy strategies involving gene transfer to DC and support the contention that results achieved in murine tumour models using human adenovirus vectors 19, [22] [23] [24] 29 will be applicable to human disease.
Results
Derivation and characterisation of DC Human DC were derived from the adherent fraction of healthy donor PBMC by culture in defined medium containing human GM-CSF and IL-4. After 7 days culture, the cell population routinely contained 50 to 90% DC by immunophenotypic (Table 1 ) and morphologic criteria ( Figure 1) . Appearance of the DC phenotype was associated with loss of the monocyte-macrophage marker CD14, which was initially expressed on greater than 90% of cells (not shown) and acquisition of CD1a expression (Table  1) . 
Adenovirus transduction of DC
The efficiency of adenovirus vector-mediated gene transfer to DC, monocytes and T-lymphocytes was assessed by histochemical analysis of ␤-gal expression 48 h after adenovirus vector exposure. DC were permissive for adenovirus vector-mediated gene transfer but required high MOI to achieve consistently high transduction rates.
At an MOI of 1000, transduction rates ranged between 38 and 100% in samples from 10 different donors (mean ± s.e.m.; 72% ± 8%). In contrast, monocytes were approximately 100-fold less permissive at the same MOI. At MOI between 10 and 1000 the correlation with transduction rate was approximately linear for monocytes, but distinctly non-linear for DC, where a sharp increase in transduction rate was observed when the MOI exceeded 100
( Figure 2a ). T-lymphocytes were even less permissive than monocytes with a transduction rate of less than 0.05% at an MOI of 10 000 (data not shown). Transgene expression in DC was followed over time after adenovirus transduction at an MOI of 100. The proportion of DC positive for ␤-gal expression peaked at 1 to 3 days and thereafter declined by approximately one half every 3 days until termination of the experiment at day 15 ( Figure 2b ).
Characterisation of DC after adenovirus transduction
Flow cytometric analysis of the cell surface molecules, CD1a, CD14, MHC class-I, MHC class-II, CD80 and CD86 was performed at 48 h after vector exposure to examine the impact of adenovirus transduction on DC phenotype. Transductions were performed at MOI of 10 and 1000. With the exception of CD86 expression, which appeared to be up-regulated, adenovirus transduction had no effect on expression of the cell surface molecules examined ( Figure 3 ). Interestingly, the CD86 expression profile was bimodal with an increased proportion of DC exhibiting high level CD86 expression after exposure to adenovirus vector ( Figure 3 , bottom panel). The mean fluorescence indices were 13 ± 2 (s.d.) and 86 ± 14 for the low and high CD86-expressing populations' respectively. Before aden- ovirus transduction the percentage of CD86-positive DC with high level expression was 33% and after adenovirus transduction at MOI of 10 and 1000 this value increased to 40% and 58%, respectively. In addition to preservation of DC phenotype, adenovirus transduction at MOI as high as 1000 had no appreciable effect on DC morphology ( Figure 4 ) or DC potency in allogeneic Tlymphocyte proliferation assays ( Figure 5 ).
Induction and analysis of CTL activity against a vectorencoded antigen Cytotoxic T-lymphocytes were generated by six cycles of exposure to ␥-irradiated adenovirus vector-transduced DC which were freshly prepared for each cycle. During the first cycle, which was performed in the absence of IL-2, there was no significant change in T-lymphocyte numbers. IL-2 was omitted during this initial cycle to minimise non-specific lymphocyte stimulation. During subsequent cycles, which were performed in the presence of IL-2, there was vigorous T-lymphocyte proliferation and increasingly rapid destruction of adenovirus-transduced DC. By the second cycle transduced DC were completely destroyed within 4 days, and by the 4th cycle within 3-4 h. This destruction of adenovirus-transduced DC occurred irrespective of whether the DC had received prior irradiation. Moreover, after four cycles of stimulation with transduced DC, the activated T cells were also capable of killing untransduced DC treated with heatinactivated adenovirus vector, with significant cytolytic activity observed within 24 h. This effect is indicative of an immune response to adenoviral proteins (data not shown).
CTL activity against the vector-encoded transgene was assayed after four and six cycles of stimulation by using an LDH-release assay. Autologous skin fibrobasts from a single donor were used as targets after retroviral transduction with vectors encoding human placental AP (LAPSN) or bacterial ␤-gal (L␤geo), or after transient transduction with the adenovirus vector Ad5CMV␤-Gal as a positive control. After four cycles of stimulation, vigorous CTL activity was detected against autologous fibroblasts transduced with the adenovirus vector at high MOI, but again not against L␤geo-transduced fibroblasts expressing ␤-gal (data not shown). After six cycles, CTL activity against L␤geo-transduced fibroblasts was detected ( Figure 6 ). This result was reproduced in a second independent experiment (not shown). In each of these experiments the percentage killing of L␤geo-transduced fibroblasts expressing ␤-gal was approximately equivalent to that of fibroblasts transduced with Ad5CMV␤-Gal at an MOI of 1. CTL activity against fibroblasts transduced with Ad5CMV␤-Gal at MOI of 10 and 100 was consistently higher. The donor used in these experiments had a low antibody titre against adenovirus by complement fixation (BioWhittaker, Walkersville, MD, USA), indicative of previous exposure (data not shown).
Discussion
The immense potential of DC as cellular adjuvants for cancer immunotherapy has been well demonstrated in murine models [16] [17] [18] [19] [20] [21] [22] [23] [24] and in human clinical trials. 25, 26 Critical to the success of this therapeutic strategy is the ability to load DC with tumour antigen(s) effectively, while preserving the complex repertoire of DC functions necessary for efficient induction of immune responses. 8, 36 Accordingly, much research is being directed towards developing and evaluating strategies for antigen loading of DC. 15, 28 Several recent studies have demonstrated that adenovirus vectors transduce both murine and human DC with high efficiency. 19, [22] [23] [24] [28] [29] [30] In mice, DC transduced with adenovirus vectors encoding a tumourassociated antigen retain the capacity to induce therapeutic antitumour immunity 19, 22, 24 despite evidence that transduction at high MOI can impair DC potency in allogeneic lymphocyte proliferation assays. 24 There are no comparative human in vivo data and little in vitro data. 28 In the current in vitro study we set out to explore the potential of adenovirus vectors in the transduction of human PBMC-derived DC, with particular emphasis on the impact of transduction on DC function. We employed an E1/E3-deleted adenovirus type 5 vector encoding bacterial ␤-gal as a target antigen. We demonstrate that, although high vector MOI are required to achieve efficient transduction (Figure 2a) , genetically modified DC continue to express cell surface MHC and costimulatory molecules (Figure 3 ) and retain their characteristic potency in the stimulation of allogeneic T-lymphocyte proliferation ( Figure 5 ). Most importantly, transduced DC are capable of inducing CTL responses against a defined vector-encoded antigen ( Figure 6 ).
While these in vitro studies using human cells clearly demonstrate the potential of adenovirus vectors in DC vaccine strategies, they also focus attention on key questions that will ultimately require analysis in humans. 
Figure 5 Dendritic cell potency in an allogeneic T-lymphocyte proliferation assay before and after adenovirus transduction at an MOI of 1000. Note the 100-fold greater potency of DC (grey) in the stimulation of allogeneic T-lymphocyte proliferation relative to the monocytic cell population (white) from which they were derived. Transduced DC were even more potent (black). Error bars represent s.e.m., n = 3.
Foremost among these questions is the impact of adenovirus transduction on the function and fate of DC in vivo. For example, (1) do adenovirus-transduced DC need to migrate to lymphoid tissues to be an effective vaccine? (2) Does adenovirus transduction impair this process? (3)
Figure 6 CTL killing of autologous fibroblast target cells expressing ␤-gal. Cytotoxicity was assayed by LDH release. Target cells: fibroblasts transduced with a retroviral vector encoding human placental alkaline phosphatase (FB-AP), fibroblasts transduced with a retroviral vector encoding bacterial ␤-gal (FB-␤-Gal), fibroblasts transduced with the adenovirus vector Ad5CMV␤-Gal at multiplicities of infection of 1, 10 and 100 (FB-Ad 1, 10 and 100, respectively). Error bars represent s.e.m., n = 3.
What effect might prior exposure of the host to adenovirus infection have on vaccine efficacy?
In our study, sequential rounds of stimulation of autologous T-lymphocytes with adenovirus-transduced DC resulted in an increasingly vigorous CTL response against adenovirus-transduced autologous fibroblasts which preceded the detection of CTL reactive against the vector-encoded antigen, ␤-gal. Moreover, the appearance of this CTL activity correlated with the appearance of cytolytic activity against DC treated with heat-inactivated adenovirus vector incapable of ␤-gal transduction. This observation is consistent with the early CTL activity being directed against adenoviral proteins. Our data however, do not allow direct quantitative comparison between CTL against adenoviral proteins and CTL against the vector-encoded transgene ␤-gal. Irrespective of the relative magnitude of these responses the observation of early CTL against adenoviral proteins is of practical importance and may reflect a predominance of viral antigens and/or the prior exposure of the donor to adenovirus infection. Whatever the mechanism, rapid clearance of transduced DC in vivo could reduce the prospect of inducing an effective immune response against a vector-encoded transgene. Alternatively anti-adenoviral immune responses might act as an adjuvant to prime antitransgene immunity as has already been observed for adenoviral proteins in the context of non-DC targeted vaccination strategies. 37 In vivo studies are required to explore definitively these possibilities.
Transduction studies performed on murine and human DC have consistently demonstrated that DC are relatively refractory to adenovirus-mediated gene transfer at low vector MOI, but that high transduction rates can be achieved at MOI of 100 to 1000. 20, 22, 24, 28, 29 One group employing PBMC-derived DC has reported a 90% transduction efficiency at an infectious MOI of 50 estimated from a particle MOI of 5000. 30 This result however, was achieved in combination with liposomes which were shown to enhance transduction efficiency several fold. These data are therefore consistent with our own and earlier studies. Why human and murine DC should require high MOI for efficient transduction remains poorly understood, although inefficient virion binding and internalisation is the most probable explanation. Adenovirus entry into cells involves complex primary and secondary interactions between cell surface molecules, including alpha v integrins and CAR, and the viral fibre and penton base proteins. [38] [39] [40] [41] Interestingly, alpha v integrin expression has been shown to be limiting in adenoviral transduction of human PBMC 39 and a similar phenotype might be retained in PBMC-derived DC. Interestingly alpha v integrin expression has been shown to limit adenoviral transduction in an immortalized DC line consistent with this possibility. 29 Further studies are required to resolve this question.
This requirement for high MOI is unlikely to present a direct problem for vaccine strategies employing human DC because these cells also appear to be relatively resistant to adenovirus-induced cytopathic effects. In our own and one earlier study, 28 human DC transduced with an MOI of 1000 remained viable in culture for at least a week. Furthermore, transduction of human DC at these high MOI did not appear to impair DC antigenpresenting potency as defined by the ability to stimulate allogeneic T-lymphocyte proliferation. Indeed, we observed increased CD86 expression following adenoviral transduction, a finding reminiscent of the effect of TNF-␣ on DC maturation and acquistion of increased antigen-presenting potency. 30 One potential negative consequence, however, of the requirement for high MOI is the exposure of DC to increased amounts of exogenous adenoviral protein. This viral protein could be captured by DC, enter the endocytic pathway and be processed for presentation by MHC class-II molecules. 8 As discussed earlier, smaller amounts of exogenous adenoviral antigen might also reach the MHC class-I processing pathway. 4, 5 The overall effect might be to increase the vigour of host immune responses against adenovirus-transduced DC, accelerating DC clearance and thereby reducing exposure of the host immune system to the vector-encoded transgene. Host immune responses might also limit effective repeat vaccination using adenovirus-transduced DC. Should rapid clearance of adenovirus-transduced DC prove to be problematic in the clinical implementation of adenovirus-DC vaccine strategies there is much that can be done to blunt this effect. Possibilities include the use of recently described adenovirus vectors that have had all viral coding sequences removed 42 to reduce endogenous production of adenoviral antigens in transduced DC and more efficient targeting of DC using tropism-modified vectors, 41 thus reducing the MOI required and therefore exposure to exogenous adenoviral antigens.
Our in vitro demonstration that human DC transduced with an adenovirus vector can induce CTL responses against a defined vector-encoded antigen reinforces the promise of adenovirus vectors in vaccine strategies employing DC. Moreover, these results provide an essential link between existing animal data and prospective human clinical trials.
Materials and methods

Cell culture
Human DC were derived from the adherent fraction of healthy donor PBMC by culture in defined medium containing GM-CSF and IL-4, as previously described, 12, 13 with the following modifications. Briefly, 5-20 × 10 6 PBMC isolated using Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) were resuspended in 2 ml of AIM V medium (serum-free lymphocyte medium, therapeutic grade, Life Technologies, Gaithersburg, MD, USA) supplemented with 50 mol/l 2-mercaptoethanol, 50 U/ml penicillin and 50 g/ml streptomycin and allowed to adhere to a six-well plastic tissue culture plate (Falcon; Becton Dickinson, Lincoln Park, NJ, USA) for 2 h. Nonadherent cells were removed by gentle washing with phosphate-buffered saline (PBS) and the remaining adherent cell fraction maintained in 2 ml AIM V supplemented with 1000 U/ml human recombinant GM-CSF (Schering-Plough, Madison, WI, USA) and 500 U/ml human recombinant IL-4 (Genzyme, Cambridge, MA, USA) for 7 days with one half volume medium change on day 3. At the end of the 7-day incubation period DC were recovered by gentle washing. Autologous and allogeneic T-lymphocytes were fractionated from PBMC using the SRBC rosetting method. Primary autologous skin fibroblasts were isolated from a donor by punch biopsy taken from the volar surface of the forearm. Tissue was minced into a fine slurry and incubated for 8 days in a 1:1 (vol/vol) mixture of Chang complete medium and DMEM supplemented with 14% bovine calf serum, 50 U/ml penicillin, 50 g/ml streptomycin, 50 g/ml gentamicin and 1 g/ml fungisone. Once a primary culture was established, cells were subsequently maintained 851 in DMEM supplemented with 10% bovine calf serum and antibiotics as described above, routinely passaged at a 1:3 dilution when confluent and used within 10 passages. All cell culture was performed at 37°C in a humidified atmosphere containing 5% CO 2 .
Viral vectors
The adenovirus vector Ad5CMV␤-Gal has been described previously. 43 This vector is deleted in the E1 and E3 regions and encodes bacterial ␤-gal under the transcriptional control of a CMV immediate-early promoter. Vector stocks were propagated on 293 cells 44 and purified as previously described. 45 Transduction titers were assigned on 293 cells by histochemical staining for ␤-gal expression 24 h after vector exposure. The retroviral vector LAPSN which encodes human placental alkaline phosphatase (AP) under the transcriptional control of the Moloney murine leukaemia virus (MLV) long terminal repeat (LTR) promoter and bacterial neomycin phosphotransferase (neo) under the transcriptional control of an SV40 early promoter has been described. 46 The retroviral vector L␤geo was constructed from the LXSN backbone (Genbank accession No. M28248) by using standard molecular techniques (sequence available on request). This vector encodes a single fusion protein (␤geo) with both bacterial ␤-gal and neomycin phosphotransferase activities 47 under the transcriptional control of an MLV LTR promoter. Retroviral vector stocks were produced by using PA317 amphotropic packaging cells 48 and titered as previously described. 49 All vector stocks were stored at −70°C until use.
Transduction and analysis of gene transfer
Except where indicated, adenovirus transduction of DC was performed in serum-free media. For analysis of transduction efficiency, 10 5 DC were suspended in 1 ml AIM V and exposed to the adenovirus vector at MOI ranging from 1 to 1000 for 2 h at 37°C. Vector-exposed cells were then washed three times in PBS and resuspended in fresh cytokine-supplemented medium. Transduction was assayed at defined intervals between 0.5 to 15 days later by histochemical staining for ␤-gal activity as previously described. 50 Flow cytometry and immunofluorescence confocal microscopy (ICM) Flow cytometry was performed on a FACScan cytometer (Becton Dickinson, Mountain View, CA, USA) according to the manufacturer's protocols. ICM was performed using a Leitz (Heidelberg, Germany) CLSM confocal microscope as described. 51 Murine antibodies used were anti-CD1a-RD(T6-RD1), CD56 
Generation of cytotoxic T-lymphocytes
Freshly prepared DC were exposed to Ad5CMV␤-Gal at MOI of 500 to 1000 for 2 h in serum-free AIM V medium, washed three times in PBS, cultured for 48 h, washed a further three times in PBS, ␥-irradiated with 2500 rads and transferred into a 12-well tissue culture plate (Falcon) at 1 × 10 5 cells per well. Freshly isolated autologous Tlymphocytes were added to achieve a 10:1 excess over DC and incubated in 2 ml of AIM V medium in the absence of IL-2 for 1 week. Activated T-lymphocytes were retrieved by Ficoll-Hypaque density gradient centrifugation and replated with freshly transduced DC. For subsequent cycles of lymphocyte stimulation the culture medium was changed to RPMI 1640 supplemented with 5% human AB serum and 10 units/ml recombinant human IL-2 (Genzyme). This process was repeated for up to a total of six cycles with one half volume media changes in the middle of each cycle. The effector population generated was CD56 
/16
− by flow cytometric analysis and remained greater than 95% CD3 + .
Preparation of fibroblast targets for CTL assays
Autologous fibroblasts constitutively expressing human placental AP or bacterial ␤-gal were generated by exposing exponentially growing cells to the retroviral vectors LAPSN or L␤geo respectively, in the presence of 5 g/ml protamine sulphate, followed by G418 selection for 14 days at a concentration of 0.5 mg/ml (active drug). Histochemical analysis of LAPSN and L␤geo-transduced fibroblast populations immediately after selection revealed that greater than 80% of cells expressed the respective transgenes. The expression of AP in LAPSNtransduced fibroblasts was stable, while ␤-gal expression in L␤geo-transduced fibroblasts exhibited a progressive decline over time. L␤geo-transduced fibroblasts were used as targets in CTL assays when the proportion of cells positive for ␤-gal expression by histochemical analysis was approximately 10%. Transduction of autologous fibroblasts with the adenovirus vector, Ad5CMV␤-Gal, was performed at MOI of 1, 10 and 100 transducing units per cell resulting in transduction efficiencies of 7%, 63% and 100%, respectively, at 48 h after vector exposure.
Analysis of cytotoxic T-lymphocyte activity
An LDH release (CytoTox 96) was used to assay CTL activity according to the manufacturer's protocol (Promega, Madison, WI, USA) with the following modifications. Target fibroblasts transduced with the retroviral vectors L␤geo or LAPSN (control), or the adenovirus vector Ad5CMV␤-Gal were trypsinised, washed three times in PBS and plated in triplicate in 24-well plates (Falcon) at 1 × 10 5 cells per well. After four to six cycles of stimu-lation by adenovirus-transduced DC, autologous Tlymphocytes were added to achieve an effector to target cell ratio of 10:1 and incubated in 1 ml RPMI1640 medium supplemented with 5% human AB serum and 10 units/ml human IL-2. Supernatants were harvested for analysis after 20 h.
